U.S. Markets closed

Oncolytics Biotech Inc. (ONC.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
0.69+0.02 (+2.99%)
At close: 3:57PM EDT
Full screen
Previous Close0.67
Open0.67
Bid0.67 x 0
Ask0.69 x 0
Day's Range0.63 - 0.69
52 Week Range0.19 - 1.13
Volume317,050
Avg. Volume186,074
Market Cap96.2M
Beta2.40
PE Ratio (TTM)-5.15
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Research3 days ago

    Oncolytics’ (ONCYF) End of Phase II Meeting

    By John Vandermosten, CFA OTC:ONCYF TSX:ONC.V Oncolytics Biotech (OTC:ONCYF) (TSX:ONC.TO) announced a successful end of Phase II meeting with the FDA in a September 18 press release.  The purpose of the ...

  • Zacks Small Cap Researchlast month

    Oncolytics’ (ONCYF) Second Quarter Results

    Oncolytics Biotech, Incorporated’s (ONCYF) second quarter began with a rush of activity as the company presented compelling data from its IND 213 study at AACR followed by an announcement of fast track designation by the FDA and presentation at ASCO in May.  The strong data from the metastatic breast cancer trial indicated a 17 month benefit from REOLYSIN (compared to 10 months for chemotherapy alone) and opens the opportunity for breakthrough designation which could be announced in October.  In preparation for a Phase III trial, Oncolytics raised additional capital in May which is expected to fund operations until late next year. The second half of 2017 will emphasize the interactions with the FDA and how this will impact the design of the Phase III trial for metastatic breast cancer.  There is also the possibility to receive breakthrough designation which will expedite the FDA’s review of REOLYSIN.  Potential collaborators are watching this process closely and we anticipate that there will be more to announce regarding a partner for the Phase III trial before the end of the year.

  • Associated Press2 months ago

    Oncolytics reports 2Q loss

    On a per-share basis, the Calgary, Alberta-based company said it had a loss of 2 cents. The company's shares closed at 40 cents. A year ago, they were trading at 32 cents. _____ This story was generated ...